{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:35:06Z","timestamp":1767591306650,"version":"3.48.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The BIOPSTAGE trial investigates the added diagnostic value of combining prostate-specific membrane antigen positron emission tomography (PSMA PET) with multiparametric MRI (mpMRI) for non-invasive detection of clinically significant prostate cancer (csPCa). This interim analysis aimed to retrospectively optimize semiquantitative PSMA PET thresholds and evaluate potential biopsy reduction through integrated imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, single-institution study, 96 men with suspected prostate cancer underwent mpMRI and PSMA PET prior to biopsy. csPCa was defined as ISUP grade group \u22652. Receiver operating characteristic (ROC) analysis identified optimal thresholds for SUVmax (\u22659.1) and SUVratio (\u22653.6). Diagnostic performance metrics (sensitivity, specificity, predictive values, and biopsy burden) were evaluated for mpMRI, PSMA PET, and their combination. Logistic regression and McNemar\u2019s test assessed predictors and comparative accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>mpMRI alone achieved a sensitivity of 93.8%, specificity of 54.6%, and an AUC of 0.74. Among the 74 lesions identified by mpMRI, 14 also met semiquantitative PET positivity criteria. An additional 11 PET-positive lesions were detected without corresponding mpMRI abnormalities. Another 60 lesions were mpMRI-positive but PET\u2013negative and would not have been targeted in an integrated strategy. If biopsy had been guided exclusively by PSMA PET\u2013positive lesions, 25 targets would have been sampled\u2014representing an approximately 66.2% reduction compared to 74 lesions identified by mpMRI alone. This biopsy reduction was associated with significantly improved specificity (McNemar\u2019s p &amp;lt; 0.001). Integrated imaging diagnostic accuracy was: sensitivity 85.7% (95% CI: 60.1\u201396.0%), specificity 86.3% (95% CI: 78.0\u201391.8%), PPV 48.0%, NPV 97.6%. Two small csPCa lesions missed by PSMA PET were PI-RADS 4, ISUP Grade Group 2. One csPCa lesion detected exclusively by PSMA PET was not visible on mpMRI (ISUP Grade Group 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrating semiquantitative PSMA PET with mpMRI improves lesion-level specificity and was associated with a theoretical reduction of approximately two-thirds in the number of targeted biopsy cores, while maintaining high sensitivity. While PSMA PET enhances risk stratification, mpMRI remains essential\u2014particularly for detecting small or PSMA-negative tumors. These interim findings support feasibility of a dual-imaging biopsy triage strategy, pending validation in the full BIOPSTAGE cohort and future multicenter trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1720861","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:27Z","timestamp":1767591027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward a PSMA PET\u2013mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial"],"prefix":"10.3389","volume":"15","author":[{"given":"Monica","family":"Celli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gunelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Fragal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD012663","DOI":"10.1002\/14651858.CD012663.pub2","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: A systematic review and meta-analysis","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3631-6","article-title":"Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000528720","article-title":"Diagnostic Performance and Clinical Impact of PSMA PET\/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX)","volume":"107","author":"Lopci","year":"2023","journal-title":"Urol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-head comparison of 68 Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2022.03.003","article-title":"Diagnostic value of integrated 18 F-PSMA-1007 PET\/MRI compared with that of biparametric MRI for the detection of prostate cancer","volume":"10","author":"Zeng","year":"2022","journal-title":"Prostate Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database","volume":"65","author":"Emmett","year":"2024","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of 68 Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: A lesion-by-lesion analysis","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.7589","article-title":"Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer: A phase 3 randomized clinical trial","volume":"7","author":"Klotz","year":"2021","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143497","article-title":"Comparison of multiparametric magnetic resonance imaging with prostate-specific membrane antigen positron-emission tomography imaging in primary prostate cancer diagnosis: A systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","article-title":"Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: A systematic review and meta-analysis","volume":"7","author":"Wang","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23868","article-title":"Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells","volume":"79","author":"Kranzb\u00fchler","year":"2019","journal-title":"Prostate"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41824-023-00182-5","article-title":"Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway","volume":"7","author":"Sharma","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.204066","article-title":"Safety and diagnostic yield of 68 Ga prostate-specific membrane antigen PET\/CT-guided robotic-assisted transgluteal prostatic biopsy","volume":"303","author":"Kumar","year":"2022","journal-title":"Radiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4058-4","article-title":"Prospective comparison of 68 Ga-PSMA PET\/CT, 18 F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer","volume":"45","author":"Zacho","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1720861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:30:28Z","timestamp":1767591028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1720861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1720861"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1720861","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1720861"}}